Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH.
Mona A HegazySherif M MogawerAlshaimaa Rezk L R AlnaggarOlfat A GhoniemRasha M Abdel SamiePublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2020)
sCD163 and LPS can be used as non-invasive tools for diagnosis and grading of NAFLD severity in overweight and obese patients, thus confirming the role of dysbiosis in fat deposition and inflammation and suggesting the potential benefits of gut-microbiota-targeted therapies in restoring the gut homeostasis.